{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:46:08Z","timestamp":1792320368126,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jcjd.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:14:09Z","timestamp":1753283649000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy"],"prefix":"10.1016","volume":"49","author":[{"given":"Nadia","family":"Nadeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad Mazin","family":"Al Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-3307","authenticated-orcid":false,"given":"Asnin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4593-2852","authenticated-orcid":false,"given":"Rahaf","family":"Wardeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fauzia","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-3603","authenticated-orcid":false,"given":"Elamin Ibrahim","family":"Abdelgadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeldin","family":"Bashier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2025.07.002_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2025.07.002_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-0044-1786013","article-title":"Epidemiology, technology, and professional perspectives on diabetes in the United Arab Emirate: A focused review","volume":"7","author":"Dahmani","year":"2024","journal-title":"J Diabetes Endocr Pract"},{"key":"10.1016\/j.jcjd.2025.07.002_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-011-0002-3","article-title":"Incretin-based therapy: A powerful and promising weapon in the treatment of type 2 diabetes mellitus","volume":"2","author":"Koliaki","year":"2011","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jcjd.2025.07.002_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review","volume":"21","author":"Bain","year":"2018","journal-title":"Diabetes Obesity Metabol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108255","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes---a systematic review and meta-analysis","volume":"36","author":"Yoshida","year":"2022","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jcjd.2025.07.002_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102696","article-title":"Glucagon-like peptide 1-receptor agonists and A1C: Good for the heart but less so for the eyes?","volume":"17","author":"Albert","year":"2023","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.jcjd.2025.07.002_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1464-5491.2007.02327.x","article-title":"Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients","volume":"25","author":"Targher","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.jcjd.2025.07.002_bib9","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic Retinopathy Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjd.2025.07.002_bib10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db16-1364","article-title":"GLP-1R as a target for the treatment of diabetic retinopathy: Friend or foe?","volume":"66","author":"Sim\u00f3","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2025.07.002_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2025.07.002_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012428","article-title":"Anti-inflammatory effects of GLP-1R activation in the retina","volume":"23","author":"Puddu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjd.2025.07.002_bib13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.102.037481","article-title":"Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4","volume":"302","author":"Perry","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcjd.2025.07.002_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.exer.2016.05.002","article-title":"The GLP-1 analogue exendin-4 attenuates oxidative stress-induced retinal cell death in early diabetic rats via promoting Sirt1 and Sirt3 expression","volume":"151","author":"Zeng","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jcjd.2025.07.002_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.peptides.2012.06.006","article-title":"Protection of exenatide for retinal ganglion cells with different glucose concentrations","volume":"37","author":"Fu","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.jcjd.2025.07.002_bib16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.exer.2014.05.004","article-title":"Exendin-4 alleviates retinal vascular leakage in diabetic rats","volume":"127","author":"Fan","year":"2014","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jcjd.2025.07.002_bib17","doi-asserted-by":"crossref","first-page":"BR35","DOI":"10.12659\/MSM.881383","article-title":"GLP-1 improves proliferation and differentiation of endothelial progenitor cells via VEGF","volume":"17","author":"Xiao-Yun","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jcjd.2025.07.002_bib18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.jcjd.2025.07.002_bib19","first-page":"S231","article-title":"Retinopathy, neuropathy, and foot care: Standards of care in diabetes---2024","volume":"47","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.07.002_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"AACE consensus statement: Comprehensive T2DM management algorithm---2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jcjd.2025.07.002_bib21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0140-6736(82)90464-0","article-title":"Worsening of diabetic retinopathy with strict control of blood sugar","volume":"2","author":"Hooymans","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2025.07.002_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2025.07.002_bib23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2025.07.002_bib24","first-page":"233","article-title":"Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18","volume":"39","author":"Davis","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjd.2025.07.002_bib25","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjd.2025.07.002_bib26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy","volume":"298","author":"Mohamed","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jcjd.2025.07.002_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2025.07.002_bib28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.diabet.2017.06.002","article-title":"Severe hypoglycaemia is a major predictor of incident diabetic retinopathy in Japanese patients with type 2 diabetes","volume":"43","author":"Tanaka","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jcjd.2025.07.002_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/dmrr.865","article-title":"Vascular disease and diabetes: Is hypoglycaemia an aggravating factor?","volume":"24","author":"Wright","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jcjd.2025.07.002_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes","volume":"44","author":"Feldman-Billard","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jcjd.2025.07.002_bib31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1\u20137 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jcjd.2025.07.002_bib32","first-page":"1","article-title":"Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy","volume":"16","author":"Chung","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib33","first-page":"287","article-title":"Effects of lipid-lowering agents on diabetic retinopathy: A meta-analysis and systematic review","volume":"11","author":"Shi","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2439691","article-title":"The relationship between peripheral nerve conduction velocity and ophthalmological findings in type 2 diabetes patients with early diabetic retinopathy","volume":"2018","author":"Ito","year":"2018","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib35","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/ajkd.1998.v31.pm9631838","article-title":"Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM","volume":"31","author":"Estacio","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jcjd.2025.07.002_bib36","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz069","article-title":"Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: The ANGIOSAFE type 2 diabetes study","volume":"105","author":"Gaborit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2025.07.002_bib37","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/biomedicines9080926","article-title":"Effects of the topical administration of semaglutide on retinal neuroinflammation and vascular leakage in experimental diabetes","volume":"9","author":"Sim\u00f3","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcjd.2025.07.002_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2025.07.002_bib39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: A meta-analysis and meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.07.002_bib40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2025.07.002_bib41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2025.07.002_bib42","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2025.07.002_bib43","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039026","article-title":"Retinopathy risk factors in patients with type 2 diabetes on liraglutide","volume":"103","author":"Mahzari","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jcjd.2025.07.002_bib44","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1111\/dom.15535","article-title":"Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes","volume":"26","author":"Popovic","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2025.07.002_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100547","article-title":"The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center","volume":"4","author":"Joo","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.jcjd.2025.07.002_bib46","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.07.002_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41433-021-01741-5","article-title":"Semaglutide and the risk of diabetic retinopathy---current perspective","volume":"36","author":"Sharma","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjd.2025.07.002_bib48","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib49","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/aogs.13309","article-title":"A simplified guide to randomized controlled trials","volume":"97","author":"Bhide","year":"2018","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jcjd.2025.07.002_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/01658107.2016.1267771","article-title":"Risk factors for non-arteritic anterior ischaemic optic neuropathy in a Korean population","volume":"41","author":"Kim","year":"2017","journal-title":"Neuro-Ophthalmology"},{"key":"10.1016\/j.jcjd.2025.07.002_bib51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ajo.2023.03.013","article-title":"Race distribution in nonarteritic anterior ischemic optic neuropathy","volume":"253","author":"Banc","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjd.2025.07.002_bib53","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish\u2013Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obesity Metab"},{"key":"10.1016\/j.jcjd.2025.07.002_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: Nonarteritic anterior ischemic optic neuropathy in the FDA Adverse Event Reporting System---a disproportionality analysis","volume":"19","author":"Azab","year":"2025","journal-title":"Obesity Res Clin Pract"},{"key":"10.1016\/j.jcjd.2025.07.002_bib55","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.orcp.2025.03.001","article-title":"Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA Adverse Event Reporting System: An emerging pharmacovigilance signal?","volume":"19","author":"Procacci","year":"2025","journal-title":"Obesity Res Clin Pract"},{"key":"10.1016\/j.jcjd.2025.07.002_bib56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib57","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2024","journal-title":"Diabetes Obesity Metabol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly Semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.jcjd.2025.07.002_bib60","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jcjd.2025.07.002_bib61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","volume":"143","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267125001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267125001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:39:47Z","timestamp":1764016787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267125001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1499267125001492"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2025.07.002","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Diabetes Canada.","name":"copyright","label":"Copyright"}]}}